Aspirin/clopidogrel - Sanofi
Alternative Names: Clopidogrel/aspirin - Sanofi; ComPlavin; DuoCover; DuoPlavinLatest Information Update: 02 Oct 2021
Price :
$50 *
At a glance
- Originator sanofi-aventis
- Developer Sanofi
- Class 2 ring heterocyclic compounds; Antiplatelets; Antipyretics; Chlorobenzenes; Esters; Pyridines; Salicylic acids; Small molecules; Thienopyridines
- Mechanism of Action Cyclooxygenase inhibitors; Platelet aggregation inhibitors; Purinergic P2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Acute coronary syndromes
Most Recent Events
- 11 Feb 2019 Chemical structure information added
- 04 Nov 2017 No recent reports of development identified for phase-I development in Acute coronary syndromes(In volunteers) in South Korea (PO, Tablet)
- 31 Mar 2015 Launched for Acute coronary syndromes in Greece, Italy, France, Portugal, Poland, Czech Republic, Croatia, Slovenia, Lithuania, Switzerland, Georgia, Russia and Ukraine (PO) before March 2015